Total revenue for the fourth quarter of 2025 was $33 million, a 24% decrease from $44 million in the comparable prior year period. Full year 2025 total revenue reached $170 million, down 25% from $227 million in the prior year. The GAAP net loss for full year 2025 improved to $(313) million, compared to $(547) million in the prior year. Adjusted EBITDA for full year 2025 improved to $(167) million, from $(293) million in the prior year. Ginkgo has agreed to sell its biosecurity business to a consortium of investors in exchange for a minority equity position, with the transaction expected to close in the first half of 2026. The company is strategically focusing its investments on autonomous labs offerings, planning to expand its frontier autonomous lab in Boston to include over 50 Reconfigurable Automation Carts (RACs), with 50 more expected by the end of 2026. Ginkgo projects a total cash burn of $(150) million to $(125) million for the full year 2026.